Analysts See $-0.11 EPS for OpGen (OPGN); Miller Howard Investments Has Raised Its Geo Group New Com (GEO) Holding

October 12, 2017 - By marketbeat

Analysts expect OpGen Inc (NASDAQ:OPGN) to report $-0.11 EPS on October, 23.They anticipate $0.12 EPS change or 52.17% from last quarter’s $-0.23 EPS. After having $-0.15 EPS previously, OpGen Inc’s analysts see -26.67% EPS growth. The stock increased 12.24% or $0.036 during the last trading session, reaching $0.331. About shares traded. OpGen Inc (NASDAQ:OPGN) has declined 38.60% since October 12, 2016 and is downtrending. It has underperformed by 55.30% the S&P500.

Miller Howard Investments Inc increased Geo Group Inc New Com (GEO) stake by 47.88% reported in 2017Q2 SEC filing. Miller Howard Investments Inc acquired 84,824 shares as Geo Group Inc New Com (GEO)’s stock rose 3.68%. The Miller Howard Investments Inc holds 261,991 shares with $7.75M value, up from 177,167 last quarter. Geo Group Inc New Com now has $3.23B valuation. The stock decreased 0.42% or $0.11 during the last trading session, reaching $26.07. About shares traded. The GEO Group Inc (NYSE:GEO) has risen 49.90% since October 12, 2016 and is uptrending. It has outperformed by 33.20% the S&P500.

Among 2 analysts covering OpGen (NASDAQ:OPGN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OpGen had 4 analyst reports since June 29, 2016 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $100 target in Wednesday, August 9 report. The firm has “Buy” rating given on Tuesday, July 18 by H.C. Wainwright. The firm has “Buy” rating by Rodman & Renshaw given on Wednesday, June 29. The firm earned “Buy” rating on Monday, September 11 by H.C. Wainwright.

OpGen, Inc. is a precision medicine firm using molecular diagnostics and informatics to combat infectious disease. The company has market cap of $17.07 million. The Firm is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. It currently has negative earnings. The Company’s deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :